Image analyses of idiopathic scoliosis sufferers using a three-dimensional, back-surface-symmetry-recognition system Top: images of a case in which a patient is to be treated with a brace. The thoracic vertebra curves by 34 degrees. Bottom: images of a case in which a patient requires surgery. The thoracic vertebra curves by 60 degrees. (a): a three-dimensional image of the back’s surface (b): based on image (a), the system evaluates the degree to which a patient’s back deviates from the ideal symmetry for a human back within a few seconds. The larger the deviation, the deeper the color. (c): comparison to X-ray photos. Deviations in the image correspond with curvatures. (Credit: Hokkaido University/Noa Co., Ltd.)
Hokkaido University researchers have developed a symmetry-recognition system for the surface of the human back that can three-dimensionally detect the early stages of idiopathic scoliosis, a type of spinal deformity, without the help of a specialist doctor.
Individuals with idiopathic scoliosis, many of whom are pubescent girls, suffer from serious curvature of the spine. The disease has a characteristically high affliction rate, affecting one in 50 people.
Early detection of the progressive ailment is regarded as essential for treatment, as it is effective to wear a special brace when the spine is curved by 30 degrees or more. In recent years, genetic study of the disease has progressed, boosting the development of treatments.
ATLANTA, Nov. 21, 2016 /PRNewswire/ — Vertera Spine, a developer of medical devices using advanced biomaterial technologies, today announced that the COHERE® Cervical Interbody Fusion Device has been recognized by Orthopedics This Week as one of the Top Ten Best Spine Technologies for 2016. COHERE features Vertera Spine’s patented porous PEEK (polyetheretherketone) Scoria®biomaterial technology, a porous architecture that seamlessly integrates with solid PEEK to mimic the cancellous to cortical transition of native bone.
Every year, Orthopedics This Week recognizes the engineering teams and inventors who develop and successfully translate innovative products into clinical use to treat back pain. This year, winning technologies were selected based on creativity, innovation, demonstrated ability to solve a critical clinical problem and their potential long-term impact on improving spine surgery.
While porous metal and porous metal-coated PEEK implants have found their way into spine fusion applications, COHERE is the first and only porous PEEK fusion device to reach clinical use. By having porous PEEK Scoria on the superior and inferior sides, COHERE provides an environment that supports bony tissue ingrowth while retaining the mechanical properties and imaging capabilities of traditional PEEK. COHERE has been available under a limited market release to a select group of surgeons since May 2016.
COHERE was considered a viable recipient of this year’s Spine Technology Award due to the extensive research presented on porous PEEK Scoria. The biomaterial’s mechanical properties and in vitro cellular response are reported in a study recently published in Clinical Orthopaedics and Related Research.1 Performed by researchers at the Georgia Institute of Technology, results of the study show that porous PEEK elicits an elevated in vitro osteogenic response compared with both smooth PEEK and smooth titanium. While prior studies have shown a similar improved osteogenic response on porous titanium, this is the first study to suggest PEEK Scoria’s porous architecture can improve the osteogenic response to PEEK. Furthermore, the study also revealed that porous PEEK Scoria exhibits the appropriate fatigue strength to withstand loading seen in the spine and a higher interfacial shear strength than bone. Likewise, another study recently published in Journal of Mechanical Behavior of Biomedical Materials demonstrates that PEEK Scoria maintains its porous architecture under similar compressive loading seen in the spine while also exhibiting the same wear resistance as regular PEEK.
“We are honored to have our COHERE cervical device with porous PEEK Scoria technology selected amongst an elite group of cutting-edge technologies,” said Stephen Laffoon, Vertera Spine director of Engineering and one of the COHERE device inventors. “The recent publication of studies on porous PEEK Scoria exemplifies our continued commitment to not only validate our own porous PEEK technology, but also advance the fundamental understanding around the role of the implant in driving osseointegration.”
About Vertera Spine: Vertera Spine is a privately-held medical device company that develops and commercializes multifunctional implants that use or complement its patented porous technology to address critical clinical needs in spine surgery. The company has received funding from the National Science Foundation, Georgia Research Alliance, and Duke Angel Network to translate its growing technology portfolio into commercial products. For more information, visit www.verteraspine.com or call 678.705.9039.
COHERE and Scoria are registered trademarks of Vertera Spine.
1Torstrick FB, Gall K, et al. Do Surface Porosity and Pore Size Influence Mechanical Properties and Cellular Response to PEEK? Clinical Orthopaedics and Related Research, 2016. 474 (11): 2373-2383.
2Evans NT, Gall K, et al. Local deformation behavior of surface porous polyether-ether-ketone. Journal of Mechanical Behavior of Biomedical Materials, 2017. 65: 522-532.
Elizabeth Hofheinz, M.P.H., M.Ed. • Fri, November 18th, 2016
NuVasive, Inc. has just announced that its Integrated Global Alignment (iGA) platform now supports all spinal procedures, including cervical alignment. They have also introduced image enhancement software that allows the surgical staff to significantly reduce exposure to surgical radiation in the operating room (OR).
As indicated in the October 25, 2016 news release, “iGA is a proprietary, procedurally-integrated digital platform of specialized products designed to help surgeons achieve more precise spinal column alignment…”
To address concerns about surgeon and patient radiation exposure, “NuVasive has acquired the LessRay software technology suite from a company called SafeRay Spine…”
Asked to give details on how the technology helps surgeons “calculate, correct, confirm,” Jason Hannon, NuVasive’s president and chief operating officer, told OTW, “To optimize sagittal alignment prior to surgery, we have two software solutions to help surgeons calculate a patients pelvic parameters, Nuvaline and NuvaMap. Nuvaline is a mobile app that works on the iOS platform, with an Android version to come, and NuvaMap is computer based software which provides a more enhanced version of calculating these same parameters. NuvaMap takes the software step further by allowing a surgeon to simulate different surgical options to understand in advance, how different approaches or interbody devices might affect the outcome on a patient’s parameters.
SAN DIEGO, CA–(Marketwired – November 17, 2016) – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will be presenting at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace in New York City on Tuesday, November 29 at 11:00 a.m. ET / 8 a.m. PT.
A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.
About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,200 person workforce in more than 40 countries around the world. For more information, please visit nuvasive.com.
Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
CONTACT INFORMATION
Investor Contact: Suzanne Hatcher
NuVasive, Inc.
858-458-2240 Email contact
Media Contact: Michael Farrington
NuVasive, Inc.
858-909-1940 Email contact
UNION CITY, Calif.–(BUSINESS WIRE)–Mizuho OSI, the leading manufacturer of specialty surgical tables for spinal and orthopaedic trauma surgery and comprehensive imaging procedures, today announced their joint participation with Trilux Medical at MEDICA 2016 World Forum for Medicine in Düsseldorf Germany, November 14-17. Trilux Medical’s surgical light, pendants, and digital OR video and patient information integration equipment compliments Mizuho OSI’s portfolio of specialty surgical and general surgery tables by improving patient outcomes and delivering enhanced clinical value.
While at MEDICA, Trilux Medical, a subsidiary of the Mizuho OSI, showcased its new generation of extremely efficient and ergonomic OR lights. The Aurinio Wave is the only Operating Room light with reLED technology, providing a combination of a shadow-free illuminated field with unique depth and high color rendering. This new dimension of light enables OR teams to work with an impressive light column that allows precise focusing for illuminating deep wounds in any position. Its high-performance level, as well as simple embedding in an existing OR integration system – Paramon – makes the Aurinio Wave the ideal light source for discerning surgeons.
Trilux Medical, a Mizuho OSI company, has 100 years of experience with lighting and technology and 50 years of expertise in operating rooms and intensive care rooms combined. The company is committed to the identification of tasks, the development of ideas, and tailored specific solutions in medical technology.
Mizuho OSI is a US-based company and the leader in the markets for specialty surgery and patient positioning. For 35 years, physicians have relied on Mizuho OSI for innovative surgical tables that provide cost effective and creative solutions. The company’s portfolio includes specialty surgical tables for procedure-specific approaches that improve patient outcomes in spine and orthopedic surgeries, as well as a range of general surgical tables along with disposable and reusable surgical patient care products.
Greg Neukirch, Mizuho OSI’s Vice President of Marketing and Sales, said, “We are thrilled with this opportunity to display our products along with Trilux Medical. The compliment of products illustrates our long-term commitment to providing innovative operating room solutions.”
“MEDICA is the world’s leading trade fair for the medical industry and a perfect venue to show our organization’s dedication to understanding the needs and exceeding the expectations of our global healthcare customers,” said Ozgur Yurduozler, Director of Marketing and Product Management at Trilux Medical.
About Mizuho OSI
For over 35 years Mizuho OSI has developed healthcare products that have allowed medical professionals to better care for their patients. The largest segment of Mizuho OSI’s business focuses on specialty surgical tables that improve surgery through advanced patient positioning. The company is the leading manufacturer of specialty surgical tables for spinal and orthopedic trauma surgery as well as comprehensive imaging procedures. Mizuho OSI was founded in 1978 as Orthopedics Systems, Inc., and is now a subsidiary of the Mizuho Ikakogyo Co., Ltd., in Tokyo, Japan. Mizuho Ikakogyo was founded in 1919 and is the leading general surgical table manufacturer in Japan and Asia. Mizuho OSI is the leading orthopedic and spinal surgical table manufacturer worldwide. Mizuho OSI products are sold in the U.S. through direct sales representatives and worldwide through authorized international distributors. More information is available at: www.mizuhosi.com
TÜBINGEN & TUTTLINGEN, Germany–(BUSINESS WIRE)–SHS Gesellschaft für Beteiligungsmanagement mbH is investing in EIT Emerging Implant Technologies GmbH. EIT was established in Tuttlingen, Germany in 2014 and manufactures spinal implant cages using 3D printing technology. SHS is investing funds from its fourth fund generation to finance EIT’s international growth and development of its innovative products.
3D printing, which is also known as additive manufacturing, is used to manufacture cellular and porous implants of biocompatible titanium. These implants mimic the structure and stiffness of natural bone material more accurately than implants manufactured using traditional methods. This in turn promotes bone ingrowth following fusion operations to achieve better clinical results and reduce complication rates. In addition to this, the implants can be fitted on a patient-specific basis, which serves to increase the contact surface and reduce future risks.
“Our EIT Cellular Titanium implants provide the answer to current challenges in implant design and choice of materials as well the extreme cost pressure in medical technology. The additive manufacturing technology allows us to tackle existing problems with new solutions. Thus we can improve the benefits for patients without increasing costs, which is a clear competitive advantage”, explains Guntmar Eisen, founder and CEO of EIT. “This ensures a high level of patient satisfaction and excellent clinical results. We are looking forward to pushing ahead with our international growth, especially in the United States, and our product development with our new partner SHS.”
“EIT’s 3D-printed spine implants have already proven their superior functionality many times in practical applications, thus promoting EIT’s growth”, adds Dr. Bernhard Schirmers, Managing Partner at SHS Gesellschaft für Beteiligungsmanagement. “EIT Emerging Implant Technologies’ management team is experienced and successful in the field of spine surgery. As a medical technology investor, we look forward to supporting them on their path to increased growth.”
“With SHS, EIT is gaining a shareholder with extensive experience in this industry. Together we can enter the next stage of EIT’s growth. This includes development of the company’s innovative product portfolio as well as entering new countries”, says Guy Selbherr, Managing Director of MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg.
With a total volume of 125 million euro, the fourth SHS fund is focusing on expansion financing, changes in shareholder structures and successor situations. The Tübingen based investor is planning further acquisitions and investments in the fast-growing medical technology and life-science industries in Germany, Austria and Switzerland in the months ahead.
About EIT Emerging Implant Technologies GmbH:
EIT is the first medical device manufacturer in the orthopedic field to exclusively focus on implants that are designed and produced with additive manufacturing methods.
EIT pushes the boundaries of traditional implant manufacturing to obtain versatile, anatomically designed porous implants with increased functionality and maximal bone ingrowth capabilities for all spinal segments.
The EIT implants made of EIT Cellular Titanium® address the shortcomings of the current designs and materials, thereby ensuring optimal clinical outcomes and maximum patient satisfaction.
EIT provides a complete spinal fusion cage portfolio. Patient specific implants to help in the treatment of complex spinal disorders as well as other interesting implant concepts are in development.
EIT consists of a team of skilled and dedicated professionals with a diverse background in management, research and development and quality assurance. The team has a proven track record setting up and managing innovative spinal implant companies, and has developed an extensive network of contacts over many years including internationally renowned surgeons and opinion leaders in the field of spine surgery.
About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. SHS was founded in 1993 and has since gained extensive experience as industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s German and international investors include about the European Investment Fund, professional pension insurers, retirement funds, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company is currently investing from its fourth generation of funds, for which investors have provided 125 million euro. Equity of up to 20 million euro is invested. Transactions can be carried out in the mid double-digit million range together with a network of co-investors. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners at SHS.
WESTMINSTER, Colo., Nov. 18, 2016 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced it has received a Best New Technology Award for spine care as part of the 2016 Orthopedics This Week Spine Technology Awards. The award recognizes the company’s i-FACTOR™ Peptide Enhanced Bone Graft, the first bone graft to be approved for use in the cervical spine by the U.S. Food and Drug Administration (FDA WESTMINSTER). Award winners were announced in conjunction with the 2016 North American Spine Society (NASS) Annual Meeting, held October 26-29 in Boston, MA.
“Over the past year we have been focused on accelerating our commercialization efforts in the U.S. following the FDA Premarket Approval (PMA) of i-FACTOR Bone Graft,” said Glen Kashuba, CEO of Cerapedics. “We continue to receive outstanding feedback from surgeons across the country who are excited to have a safe, clinically effective and cost effective bone graft that is supported by Level I human data. We are grateful to be recognized by Orthopedics This Week and the surgeon panel who chose i-FACTOR Bone Graft for the Best New Technology Award.”
i‐FACTOR Bone Graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. In November 2015, i-FACTOR Bone Graft was approved by the FDA for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease.
The annual Orthopedics This Week Spine Technology Awards honor inventors, engineering teams, surgeons and their companies who have created the most innovative, enduring and practical products to treat back pain. For more information, visit https://ryortho.com/2016/11/the-ten-best-new-spine-technologies-for-2016/.
About Cerapedics
Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.
Media contact: Adam Daley
Berry & Company Public Relations
212-253-8881 adaley@berrypr.com
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced that President and Chief Executive Officer Brad Mason will present at the Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 9:10 a.m. Eastern Time in New York, NY.
A live audio webcast will be available on the Company’s website at www.orthofix.com by clicking on the Investors tab and then clicking the link on the Events and Presentations page.
About Orthofix
Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, TX, the company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the company’s sales representatives, distributors and subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as Brown University, Sinai Hospital of Baltimore, Cleveland Clinic, Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation. For more information, please visit www.orthofix.com.
SHELTON, CT–(Marketwired – November 17, 2016) – Spine Wave, Inc. is committed to the commercialization of high-quality, innovative medical devices for the treatment of spinal disorders. Spine Wave is pleased to announce that Chief Executive Officer Mark LoGuidice will present at the upcoming 28th Annual Piper Jaffray Healthcare Conference in New York City. The presentation will begin at 4:10 p.m. on Tuesday, November 29th in the Kennedy 1 Room at the Lotte New York Palace.
Mr. LoGuidice’s presentation will highlight Spine Wave’s recent commercial success with new expandable interbody product introductions, as well as provide a glimpse into the 2017 pipeline which will significantly expand both the company’s product portfolio and the addressable market segments.
About Spine Wave
Spine Wave’s vision is to leverage our intellectual property portfolio and engineering expertise to deliver a steady stream of highly differentiated spinal technologies with a particular emphasis on expandable interbody devices. Spine Wave’s portfolio of expandable products now includes the Velocity® Interbody Device, the Leva® Interbody Device and the StaXx® family of products, of which over 50,000 devices have been implanted. Other novel products in the portfolio include the Annex® Adjacent Level System, the Sniper® Spine System, which has developed a reputation as a leading MIS screw system, and the recently acquired True Position® Pivoting Spacer System which is comprised of a “crescent-style” interbody device and a unique delivery mechanism which simplifies accurate and reproducible placement of the implant. Spine Wave is committed to delivering a robust pipeline in 2017 that will allow the company to address every major spine market segment with a highly differentiated offering.
For further information on all of the Spine Wave products please visit the Company’s website at www.SpineWave.com.
CONTACT INFORMATION
Contact:
Terry Brennan
Chief Financial Officer Email contact
203-712-1810
PARIS & SAN FRANCISCO–(BUSINESS WIRE)–SpineGuard (FR0011464452 – ALSGD) announced today that it has received an award from Orthopedics this Week, one of the most widely read publications in the Orthopedics industry, recognizing SpineGuard’s innovative DSG™ (Dynamic Surgical Guidance) Screw as one of the BEST new spine care technologies for 2016. The award was received during the 31st annual meeting of the North American Spine Society (NASS) in Boston.
The DSG™ Screw is a pedicle screw with a unique combination of a bipolar sensor with a pedicle screw—in just one device. The technology gives surgeons real-time guidance and the ability to insert the screw directly into a vertebra without drilling a pilot hole.
The DSG™ sensor differentiates various tissue types based on an analysis of the local electrical conductivity (cancellous bone, cortical bone, blood and soft tissues). Real-time feedback informs the surgeon of changes in tissue type by changes in the pitch and cadence of an audio signal and a flashing LED light. This in turn alerts the surgeon of potential pedicular or vertebral breaches during pedicle screw placement.
Moreover, the use of the DSG™ screw in MIS (Minimally Invasive Spine surgery) obviates the need for a k-wire. The outcome is a single-step pedicle screw insertion with an unprecedented degree of accuracy along with the added benefits of the potential for reduced radiation exposure and streamlined surgical steps, with resulting time- and cost-savings.
The US FDA clearance process for the DSG™ Screw is in progress. The FDA dossier was submitted in conjunction with Zavation, a spinal implant company that SpineGuard has partnered with to license and co-develop a DSG-enabled Zavation SmartScrew. Once cleared, Zavation will market and sell the first DSG-enabled screw in the USA.
Pierre Jérôme, Co-founder and CEO of SpineGuard, concluded: “This award is a great recognition for the SpineGuard R&D and marketing teams, the co-inventors of the DSG™ technology, the surgeons involved in the product design, as well as NeuroFrance and Zavation, our pedicle screw partners. Given the quality of the panel who made the selection, this award is very encouraging for the future adoption of our DSG™ integration system.”
A DSG™-enabled SmartScrew co-developed with Neuro France Implants (La ville-aux-Clercs, France) is currently in alpha launch in Europe with five surgeons having started to use the system.
More information on the DSG™ technology, its new applications and surgeons’ testimonials here.
Recent events:
SpineGuard reports 50,000 spine procedures performed using its family of PediGuard devices for accurate pedicle screw placement. The PediGuard product line includes the PediGuard Straight, PediGuard Curved, PediGuard Cannulated, and PediGuard Threaded.
Latest news release: SpineGuard® expands “PediGuard®” franchise, will launch “PediGuard Threaded” drilling device at North American Spine Society (NASS) annual meeting, October 19, 2016
Next financial press release: 2016 full year revenue, January 5, 2017
About SpineGuard®
Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer by bringing real-time digital technology into the operating room. Its primary objective is to establish its proprietary DSG™ (Dynamic Surgical Guidance) technology as the global standard of surgical care, starting with safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG, was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. 50,000 surgical procedures have been performed worldwide with PediGuard. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. In 2015, SpineGuard started to expand the applications of DSG into pedicle screws through partnerships with innovative surgical companies in France and the US. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.
Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
Contacts
SpineGuard
Pierre Jérôme, +33 (0)1 45 18 45 19
Chief Executive Officer p.jerome@spineguard.com
or
Manuel Lanfossi
Chief Financial Officer m.lanfossi@spineguard.com
or Europe / NewCap
Investor Relations & Financial Communication
Florent Alba / Pierre Laurent, +33 (0)1 44 71 94 94 spineguard@newcap.fr
or US
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
